Literature DB >> 21840324

Modeling the gender-specific impact of vaginal microbicides on HIV transmission.

Dobromir T Dimitrov1, Marie-Claude Boily, Rebecca F Baggaley, Benoit Masse.   

Abstract

Vaginal microbicides (VMB) are currently among the few women-initiated biomedical interventions for preventing heterosexual transmission of HIV. In this paper we use a deterministic model of HIV transmission to assess the public-health benefits of a VMB intervention and evaluate its gender-specific impact over short (initial) and extended periods of time. We define two distinct quantitative benefit ratios (QBRs) based on infections prevented in men and women to create and study regions of male advantage in different parameter spaces. Our analysis exposes complicated temporal correlations between the QBRs and series of pre-intervention (e.g., HIV acquisition risks per act) and intervention parameters (e.g., VMB efficacy mechanisms, rates of resistance development and reversion) and indicates that different QBRs may often disagree on the gender distribution of the benefits from a VMB intervention. We also outline the strong influence of some modeling assumptions on the reported results and conclude that the assessment of VMB and other biomedical interventions must be based on more comprehensive analyses than calculations of infections prevented over a fixed period of time.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840324      PMCID: PMC3184649          DOI: 10.1016/j.jtbi.2011.08.001

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  25 in total

1.  On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations.

Authors:  O Diekmann; J A Heesterbeek; J A Metz
Journal:  J Math Biol       Date:  1990       Impact factor: 2.259

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.

Authors:  David Pao; Ushan Andrady; Janette Clarke; Gillian Dean; Susan Drake; Martin Fisher; Tanya Green; Siva Kumar; Maurice Murphy; Alan Tang; Stephen Taylor; David White; Gillian Underhill; Deenan Pillay; Patricia Cane
Journal:  J Acquir Immune Defic Syndr       Date:  2004-12-15       Impact factor: 3.731

4.  The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDS.

Authors:  R M Anderson; R M May; M C Boily; G P Garnett; J T Rowley
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

5.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

Authors:  Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn
Journal:  J Infect Dis       Date:  2005-03-30       Impact factor: 5.226

6.  Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.

Authors:  Charles J N Lacey; Anne Wright; Jonathan N Weber; Albert T Profy
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

7.  A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Authors:  Sheena McCormack; Vicky Jespers; Naomi Low-Beer; Rhian Gabe; Nicola Kaganson; Alan Chapman; Andrew Nunn; Charles Lacey; Lut Van Damme
Journal:  Sex Transm Dis       Date:  2005-12       Impact factor: 2.830

8.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

Review 9.  Shifts in condom use following microbicide introduction: should we be concerned?

Authors:  Anna M Foss; Peter T Vickerman; Lori Heise; Charlotte H Watts
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

10.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Authors:  Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

View more
  13 in total

1.  Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions.

Authors:  Yuqin Zhao; Dobromir T Dimitrov; Hao Liu; Yang Kuang
Journal:  Bull Math Biol       Date:  2013-02-23       Impact factor: 1.758

2.  What can mathematical models tell us about the relationship between circular migrations and HIV transmission dynamics?

Authors:  Aditya S Khanna; Dobromir T Dimitrov; Steven M Goodreau
Journal:  Math Biosci Eng       Date:  2014-10       Impact factor: 2.080

3.  Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions.

Authors:  Yuqin Zhao; Daniel T Wood; Hristo V Kojouharov; Yang Kuang; Dobromir T Dimitrov
Journal:  Bull Math Biol       Date:  2016-10-04       Impact factor: 1.758

4.  Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study.

Authors:  Dobromir Dimitrov; James R Moore; Daniel Wood; Kate M Mitchell; Maoji Li; James P Hughes; Deborah J Donnell; Sharon Mannheimer; Timothy H Holtz; Robert M Grant; Marie-Claude Boily
Journal:  Clin Infect Dis       Date:  2020-07-11       Impact factor: 9.079

5.  Beating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy bound.

Authors:  Dobromir T Dimitrov; Benoît R Mâsse; Marie-Claude Boily
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

6.  Modeling the impact of post-diagnosis behavior change on HIV prevalence in Southern California men who have sex with men (MSM).

Authors:  Aditya S Khanna; Steven M Goodreau; Pamina M Gorbach; Eric Daar; Susan J Little
Journal:  AIDS Behav       Date:  2014-08

7.  How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.

Authors:  Fern Terris-Prestholt; Kara Hanson; Catherine MacPhail; Peter Vickerman; Helen Rees; Charlotte Watts
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

8.  How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.

Authors:  Dobromir T Dimitrov; Marie-Claude Boily; Timothy B Hallett; Jan Albert; Charles Boucher; John W Mellors; Deenan Pillay; David A M C van de Vijver
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

9.  Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments.

Authors:  Fern Terris-Prestholt; Matthew Quaife; Peter Vickerman
Journal:  Health Econ       Date:  2016-01-15       Impact factor: 3.046

Review 10.  Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness.

Authors:  Dobromir Dimitrov; Marie-Claude Boily; Elizabeth R Brown; Timothy B Hallett
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.